培美曲塞联合顺铂治疗非鳞型非小细胞肺癌的疗效观察  

Efficacy of Pemetrexed Combined with Cisplatin in the Treatment of Non-squamous Non-small Cell Lung Cancer

作　　者：杨威 曾琼 张贵芳 鲁梅 

机构地区：[1]葛洲坝集团中心医院,443002

出　　处：《实用癌症杂志》2018年第1期66-68,共3页The Practical Journal of Cancer

摘　　要：目的探讨培美曲塞联合顺铂治疗非鳞型非小细胞肺癌的效果及不良反应。方法选取40例非鳞型非小细胞肺癌患者临床资料作为研究对象,按照入院顺序随机分为实验组与对照组,每组均为20例。对照组应用培美曲塞治疗方法,实验组应用培美曲塞联合顺铂治疗方法。采用SPSS20.0统计学软件进行统计学分析2组患者的临床治疗效果、不良反应发生率。结果实验组临床治疗总有效率为45.00%(9/20),总控制率75.00%(15/20);对照组临床治疗总有效率为30.00%(6/20),总控制率为50.00%(10/20)。实验组临床治疗效果显著优于对照组(P<0.05)。实验组不良反应发生率与对照组比较无统计学意义(P>0.05)。结论培美曲塞联合顺铂治疗非鳞型非小细胞肺癌效果较好,安全性和耐受性好。Objective To investigate the effect and adverse effects of pemetrexed combined with cisplatin in the treat- ment of non-squamous non-small cell lung cancer. Methods 40 patients with non-squamous non-small cell lung cancer were ran- domly divided into the experimental group and the control group according to the order of admission. The control group was treated with pemetrexed therapy, and the experimental group was treated with pemetrexed combined with cisplatin. SPSS 20.0 statistical software was used to analyze the clinical treatment effect and the incidence of adverse reactions in the 2 groups. Results The to- tal effective rate was 45.00% （9/20） and the total control rate was 75.00% （15/20） in the experimental group. The total effec- tive rate was 30.00% （6/20） and the total control rate was 50.00% （10/20） in the control group. The clinical treatment effect of the experimental group was significantly better than that of the control group （P 〈 0.05）. The incidence of adverse reactions of the 2 groups had no statistically significant difference （P 〉 0.05）. Conclusion Pemetrexed combined with cisplatin in the treat- ment of non-squamous non-small cell carcinoma is effective, safe and tolerant.

关 键 词：培美曲塞 顺铂 非鳞型非小细胞肺癌 应用价值 

分 类 号：R734.2[医药卫生—肿瘤]